T2 Mapping

Quibim

Quibim has developed this suite to automatically obtain the T2 mapping of tumors and depict changes and abnormalities with AI segmentation. The analysis of T2 mapping provides imaging biomarkers for the assessment and monitoring of solid tumors, such as prostate cancer, rectal cancer and liver cancer, among others.
Product specifications Information source: Vendor
Last updated: May 17, 2020
General
Product name T2 Mapping
Company Quibim
Subspeciality Abdomen, Breast
Modality MR
Disease targeted Solid tumors, Prostate cancer, Rectal cancer, Endometrial cancer, Liver cancer
Key-features T2 values, T2 Histogram
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand) (Need to draw ROI)
Data characteristics
Population Assessment and monitoring of solid tumors and cartilage changes
Input MRI T2 Multi-echo
Input format
Output One-page structured report: ROI, T2 map, T2 histogram, T2 fitting, statistics summary
Output format
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically after drawing ROI
Processing time 1 - 10 minutes
Certification
CE
Certified, Class IIa , MDD
FDA
No or not yet
Market presence
On market since 01-2019
Distribution channels
Countries present (clinical, non-research use) 2
Paying clinical customers (institutes) 5+
Research/test users (institutes)
Pricing
Pricing model License
Based on Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers Crema MD et al. Articular cartilage in the knee: current MR imaging techniques and applications in clinical practice and research. RadioGraphics 2011;31:37-61.

Sanz-Requena R et al. Modification of longitudinal relaxation time (T1) as a biomarker of patellar cartilage degeneration. Radiologia 2010;52:221-227.

Sanz R et al. MR pharmacokinetic modeling of the patellar cartilage differentiates normal from pathological conditions. J Magn Reson Imaging 2008;27:171-177.